BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27790297)

  • 21. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term results of treatment in patients with extragonadal germ cell tumours.
    Gutierrez Delgado F; Tjulandin SA; Garin AM
    Eur J Cancer; 1993; 29A(7):1002-5. PubMed ID: 7684595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.
    Takada A; Ii N; Hirayama M; Toyoda H; Matsubara T; Toyomasu Y; Kawamura T; Daimon T; Sakuma H; Nomoto Y
    J Neurosurg Pediatr; 2018 Nov; 23(3):317-324. PubMed ID: 30497152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
    Bokemeyer C; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Einhorn L; Nichols CR; Hartmann JT
    Cancer; 2001 Apr; 91(7):1394-401. PubMed ID: 11283942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
    Bower M; Newlands ES; Holden L; Rustin GJ; Begent RH
    Ann Oncol; 1997 May; 8(5):477-83. PubMed ID: 9233528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy of extragonadal germ cell tumors.
    Logothetis CJ; Samuels ML; Selig DE; Dexeus FH; Johnson DE; Swanson DA; von Eschenbach AC
    J Clin Oncol; 1985 Mar; 3(3):316-25. PubMed ID: 2579212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
    J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol.
    Faure-Conter C; Orbach D; Sudour-Bonnange H; Verité C; Mansuy L; Rome A; Dumesnil C; Thebaud E; Renard M; Hameury F; Flechon A; Blanc E; Dijoud F; Fresneau B; Chabaud S
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30117. PubMed ID: 36451268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extragonadal germ cell tumors in Japan.
    Ebi H; Nakata M; Tahara M; Igarashi T; Kawada K; Itoh K; Ueda R; Minami H
    Cancer Sci; 2003 Dec; 94(12):1107-11. PubMed ID: 14662028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).
    Germà-Lluch JR; Garcia del Muro X; Maroto P; Paz-Ares L; Arranz JA; Gumà J; Alba E; Sastre J; Aparicio J; Fernández A; Barnadas A; Terrassa J; Sáenz A; Almenar D; López-Brea M; Climent MA; Sánchez MA; Lasso de la Vega R; Berenguer G; Pérez X;
    Eur Urol; 2002 Dec; 42(6):553-62; discussion 562-3. PubMed ID: 12477650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting.
    Joel A; Mathew N; Andugala SS; Daniel S; Gnanamuthu BR; John AO; Georgy JT; Chacko RT; Irodi A; Yadav B; John S; Singh A
    Ecancermedicalscience; 2021; 15():1186. PubMed ID: 33777179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extragonadal germ cell tumors. Clinicopathologic findings and treatment experience in 12 patients.
    McLeod DG; Taylor HG; Skoog SJ; Knight RD; Dawson NA; Waxman JA
    Cancer; 1988 Mar; 61(6):1187-91. PubMed ID: 2449276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
    Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
    J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers.
    De Latour B; Fadel E; Mercier O; Mussot S; Fabre D; Fizazi K; Dartevelle P
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):66-71; discussion 71. PubMed ID: 22290909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
    Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
    Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.